Outlook Therapeutics Inc 41O
Find similar stocks with Morningstar Investor.
Morningstar analysts do not currently cover 41O, but with our powerful screener, you can find stocks in the same sector, industry, or style and filter on our unbiased ratings and valuation metrics.
News
-
Outlook Therapeutics Shares Rally Premarket on ONS-5010 Advances
-
Outlook Therapeutics Shares Fall Premarket as Another ONS-5010 Study Needed
-
Outlook Therapeutics Shares Plumb New Depths After FDA Setback
-
Outlook Therapeutics Shares Plummet Premarket as FDA Rejects ONS-5010
-
Outlook Therapeutics' stock tumbles 71% premarket after FDA rejects treatment for wet AMD
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 24
Comparables
Valuation
|
Metric
|
41O
|
EQRX
|
ACLX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 0.97 | 5.84 |
Price/Sales | — | — | 20.48 |
Price/Cash Flow | — | — | 401.32 |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
41O
|
EQRX
|
ACLX
|
|---|---|---|---|
Quick Ratio | 0.87 | 18.43 | 5.32 |
Current Ratio | 1.07 | 18.78 | 5.46 |
Interest Coverage | −71.52 | — | −22.10 |
Quick Ratio
41O
EQRX
ACLX
Profitability
|
Metric
|
41O
|
EQRX
|
ACLX
|
|---|---|---|---|
Return on Assets (Normalized) | −209.78% | −15.72% | −1.99% |
Return on Equity (Normalized) | — | −16.71% | −3.75% |
Return on Invested Capital (Normalized) | −2,826.29% | −21.31% | −7.24% |
Return on Assets
41O
EQRX
ACLX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Wyrwsgbtg | Zdptw | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Jtnmgcw | Gkrrxs | $114.2 Bil | |||
| Moderna Inc
MRNA
| Jvzvqvfy | Bwpn | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Bhpdxddws | Kpb | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Bybdcdvcy | Mxc | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qmwczwtxm | Drcywh | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Kfjvvnfh | Dmkhm | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Rzwlppc | Vlxp | $12.8 Bil | |||
| Incyte Corp
INCY
| Qlfpdjn | Mjchlll | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Lzzqfqdb | Mbttysc | $12.2 Bil |